Better Buy: Biogen vs. Eli Lilly

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new therapies: Alzheimer's disease (AD).

However, these two stocks have moved in very different directions over the past three years, with Eli Lilly delivering substantially better returns to its shareholders. Will that continue to be the case? Or will Biogen be the better performer from here on out?

Source Fool.com

Biogen Inc. Aktie

Die Biogen Inc. Aktie rutscht heute leicht ab, verliert -0,58 %.
Starke Kaufneigung bei Biogen Inc., mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 203 € für Biogen Inc. impliziert eine leichte Steigerung gegenüber dem aktuellen Kurs von 178.0 €.

Like: 0

BIIB

Teilen